Decreased levels of cytochrome P450 2E1-derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats

Hypertension. 2005 Jan;45(1):103-8. doi: 10.1161/01.HYP.0000150782.28485.91. Epub 2004 Nov 29.

Abstract

We compared renal interlobar arteries of spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) in terms of cytochrome P450 (CYP) 4A and CYP2E1 protein expression; levels of 20-HETE, 19-HETE, and 18-HETE; and responsiveness to phenylephrine in the absence and presence of N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS; 30 mumol/L), a CYP4A inhibitor. Relative to data in WKY, arteries of SHR exhibited diminished (P<0.05) CYP2E1 and levels of 19-HETE (66.7+/-6.0 versus 44.9+/-2.8 pmol/mg) and 18-HETE (13.8+/-1.6 versus 7.9+/-0.5 pmol/mg), whereas CYP4A and 20-HETE levels (99.3+/-9.1 versus 98.9+/-12.8 pmol/mg) were unchanged. Phenylephrine contracted vascular rings of SHR and WKY; the R(max) was similar in both strains, but SHR vessels were more sensitive as denoted by the lower (P<0.05) EC50 (0.28+/-0.07 versus 0.71+/-0.12 mumol/L). DDMS decreased 20-HETE and, to a lesser extent, 19-HETE, while increasing (P<0.05) the EC50 for phenylephrine by 475% and 54% in vessels of SHR and WKY, respectively. The desensitizing effect of DDMS was reversed by 20-HETE. Notably, the minimal concentration of 20-HETE that decreased the EC50 for phenylephrine in DDMS-treated vessels was smaller in SHR (0.1 micromol/L) than WKY (10 micromol/L), and the sensitizing effect of 20-HETE was blunted (P<0.05) by the (R) stereoisomers of 19-HETE and 18-HETE. We conclude that the increased sensitivity to phenylephrine in arteries of SHR is attributable to a vasoregulatory imbalance produced by a deficit in vascular CYP2E1-derived products, most likely 19(R)-HETE and 18(R)-HETE, which condition amplification of the sensitizing action of 20-HETE.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amides / pharmacology
  • Animals
  • Arachidonic Acid / metabolism
  • Cytochrome P-450 CYP2E1 / deficiency
  • Cytochrome P-450 CYP2E1 / genetics
  • Cytochrome P-450 CYP2E1 / metabolism*
  • Cytochrome P-450 CYP4A / antagonists & inhibitors
  • Cytochrome P-450 CYP4A / metabolism*
  • Hydroxyeicosatetraenoic Acids / deficiency*
  • Hypertension / enzymology*
  • Hypertension / genetics
  • Hypertension / physiopathology
  • Phenylephrine / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Renal Artery / drug effects
  • Renal Artery / enzymology*
  • Sulfones / pharmacology
  • Tetraethylammonium / pharmacology
  • Vasoconstriction / drug effects
  • Vasoconstriction / genetics
  • Vasoconstriction / physiology*
  • Vasoconstrictor Agents / pharmacology*
  • Vasopressins / pharmacology

Substances

  • Amides
  • Hydroxyeicosatetraenoic Acids
  • Potassium Channel Blockers
  • Sulfones
  • Vasoconstrictor Agents
  • Vasopressins
  • Phenylephrine
  • 18-hydroxy-5,8,11,14-eicosatetraenoic acid
  • Arachidonic Acid
  • Tetraethylammonium
  • 19-hydroxy-5,8,11,14-eicosatetraenoic acid
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid
  • DDMS
  • Cytochrome P-450 CYP2E1
  • Cytochrome P-450 CYP4A